Reviews in Endocrine and Metabolic Disorders

, Volume 10, Issue 3, pp 167–188

Identification and treatment of metabolic complications in pediatric obesity

  • Katie Larson Ode
  • Brigitte I. Frohnert
  • Brandon M. Nathan


Metabolic consequences of obesity including insulin resistance, type 2 diabetes mellitus, hyperlipidemia, hypertension, polycystic ovarian syndrome, and non-alcoholic fatty liver infiltration are rapidly emerging in the pediatric population. Identifying effective strategies for identifying and treating these obesity related co-morbidities in children are crucial to the prevention of future cardiovascular disease and poor health outcomes. This review discusses the pathophysiologic connections between obesity, metabolic disease and cardiovascular risk. Current evidence and recommendations for screening and treatment for the metabolic consequences of pediatric obesity are reviewed.


Insulin resistance Fatty liver disease Type 2 diabetes mellitus Polycystic ovary disease Metabolic syndrome 


  1. 1.
    Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55.PubMedCrossRefGoogle Scholar
  2. 2.
    Dabelea D, Bell RA, D’Agostino RB, Imperatore G, Johansen JM, Linder B, et al. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50:957–69.PubMedCrossRefGoogle Scholar
  4. 4.
    González F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metab Clin Exp. 2009;58:954–62.PubMedGoogle Scholar
  5. 5.
    Savoia C, Schiffrin EL. Reduction of C-reactive protein and the use of anti-hypertensives. Vasc Health Risk Manag. 2007;3:975–83.PubMedGoogle Scholar
  6. 6.
    Rueda-Clausen CF, López-Jaramillo P, Luengas C, del Pilar Oubiña M, Cachofeiro V, Lahera V. Inflammation but not endothelial dysfunction is associated with the severity of coronary artery disease in dyslipidemic subjects. Mediators Inflamm 2009. 2009;2009:469169.Google Scholar
  7. 7.
    Gozal D, Kheirandish-Gozal L. Cardiovascular morbidity in obstructive sleep apnea:oxidative stress, inflammation, and much more. Am J Respir Crit Care Med. 2008;177:369–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:S64–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Nemet D, Wang P, Funahashi T, Matsuzawa Y, Tanaka S, Engelman L, et al. Adipocytokines, body composition, and fitness in children. Pediatr Res. 2003;53:148–52.PubMedGoogle Scholar
  10. 10.
    Anty R, Bekri S, Luciani N, Saint-Paul M, Dahman M, Iannelli A, et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol. 2006;101:1824–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Bisoendial RJ, Birjmohun RS, Akdim F, Van ’t Veer C, Spek CA, Hartman D, et al. C-reactive protein elicits white blood cell activation in humans. Am J Med. 2009;122:582.e1-9.PubMedCrossRefGoogle Scholar
  12. 12.
    Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk:moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129–38.PubMedCrossRefGoogle Scholar
  13. 13.
    Venner AA, Lyon ME, Doyle-Baker PK. Leptin:a potential biomarker for childhood obesity? Clin Biochem. 2006;39:1047–56.PubMedCrossRefGoogle Scholar
  14. 14.
    Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413–37.PubMedCrossRefGoogle Scholar
  15. 15.
    Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998;12:57–65.PubMedGoogle Scholar
  16. 16.
    Bastard J, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.PubMedGoogle Scholar
  17. 17.
    Plaisance EP, Grandjean PW, Judd RL, Jones KW, Taylor JK. The influence of sex, body composition, and nonesterified fatty acids on serum adipokine concentrations. Metab Clin Exp. 2009; doi:10.1016/j.metabol.2009.04.038.
  18. 18.
    Böttner A, Kratzsch J, Müller G, Kapellen TM, Blüher S, Keller E, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab. 2004;89:4053–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Gavi S, Qurashi S, Stuart LM, Lau R, Melendez MM, Mynarcik DC, et al. Influence of age on the association of retinol-binding protein 4 with metabolic syndrome. Obesity (Silver Spring). 2008;16:893–5.CrossRefGoogle Scholar
  21. 21.
    Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30.PubMedCrossRefGoogle Scholar
  22. 22.
    Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6:363–75.PubMedCrossRefGoogle Scholar
  23. 23.
    Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans. Clin Endocrinol (Oxf). 2009;71:202–7.CrossRefGoogle Scholar
  24. 24.
    Badman MK, Flier JS. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology. 2007;132:2103–15.PubMedCrossRefGoogle Scholar
  25. 25.
    Vachharajani V, Granger DN. Adipose tissue: a motor for the inflammation associated with obesity. IUBMB Life. 2009;61:424–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, et al. Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome. Metab Clin Exp. 2008;57:1539–44.PubMedGoogle Scholar
  27. 27.
    Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care. 2005;28:878–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Valle M, Martos R, Gascón F, Cañete R, Zafra MA, Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Metab. 2005;31:55–62.PubMedCrossRefGoogle Scholar
  29. 29.
    Wärnberg J, Marcos A. Low-grade inflammation and the metabolic syndrome in children and adolescents. Curr Opin Lipidol. 2008;19:11–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Wärnberg J, Nova E, Romeo J, Moreno LA, Sjöström M, Marcos A. Lifestyle-related determinants of inflammation in adolescence. Br J Nutr. 2007;98(Suppl 1):S116–20.PubMedGoogle Scholar
  31. 31.
    Cizmecioglu F, Etiler N, Ergen A, Keser A, Hekim N, Hamzaoglu O, et al. Association of Adiponectin, Resistin and High Sensitive CRP Level with the Metabolic Syndrome in Childhood and Adolescence. Exp Clin Endocrinol Diabetes. 2009; doi:10.1055/s-0028-1112151.
  32. 32.
    McGill HC, McMahan CA. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol. 1998;82:30T–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:367–77.PubMedCrossRefGoogle Scholar
  35. 35.
    Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Nathan BM, Moran A. Metabolic complications of obesity in childhood and adolescence:more than just diabetes. Curr Opin Endocrinol Diabetes Obes. 2008;15:21–9.PubMedGoogle Scholar
  37. 37.
    Huerta MG, Roemmich JN, Kington ML, Bovbjerg VE, Weltman AL, Holmes VF, et al. Magnesium deficiency is associated with insulin resistance in obese children. Diabetes Care. 2005;28:1175–81.PubMedCrossRefGoogle Scholar
  38. 38.
    Krekoukia M, Nassis GP, Psarra G, Skenderi K, Chrousos GP, Sidossis LS. Elevated total and central adiposity and low physical activity are associated with insulin resistance in children. Metab Clin Exp. 2007;56:206–13.PubMedGoogle Scholar
  39. 39.
    Schwartz B, Jacobs DR, Moran A, Steinberger J, Hong C, Sinaiko AR. Measurement of Insulin Sensitivity in Children:Comparison Between the Euglycemic Hyperinsulinemic Clamp and Surrogate Measures. Diabetes Care. 2008;31:783–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Eyzaguirre F, Mericq V. Insulin resistance markers in children. Horm Res. 2009;71:65–74.PubMedCrossRefGoogle Scholar
  41. 41.
    Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among U.S. adolescents:a population-based study. Diabetes Care. 2006;29:2427–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Sinaiko AR, Steinberger J, Moran A, Hong C, Prineas RJ, Jacobs DR. Influence of insulin resistance and body mass index at age 13 on systolic blood pressure, triglycerides, and high-density lipoprotein cholesterol at age 19. Hypertension. 2006;48:730–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Sinaiko AR, Jacobs DR, Steinberger J, Moran A, Luepker R, Rocchini AP, et al. Insulin resistance syndrome in childhood:associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. J Pediatr. 2001;139:700–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Williams DE, Cadwell BL, Cheng YJ, Cowie CC, Gregg EW, Geiss LS, et al. Prevalence of impaired fasting glucose and its relationship with cardiovascular disease risk factors in US adolescents, 1999–2000. Pediatrics. 2005;116:1122–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Oliveira AC, Oliveira AM, Adan LF, Oliveira NF, Silva AM, Ladeia AM. C-reactive protein and metabolic syndrome in youth:a strong relationship? Obesity (Silver Spring). 2008;16:1094–8.CrossRefGoogle Scholar
  46. 46.
    Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, McCrindle B, et al. Progress and challenges in metabolic syndrome in children and adolescents:a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young;Council on Cardiovascular Nursing;and Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2009;119:628–47.PubMedCrossRefGoogle Scholar
  47. 47.
    Sinaiko AR, Steinberger J, Moran A, Prineas RJ, Vessby B, Basu S, et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation. 2005;111:1985–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Morrison JA, Friedman LA, Wang P, Glueck CJ. Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J. Pediatr. 2008;152:201–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Sanders BH, Lubsch LM, West DS. Prevalence and treatment of metabolic syndrome in adolescents with type 2 diabetes. Ann Pharmacother. 2006;40:1517–21.PubMedCrossRefGoogle Scholar
  50. 50.
    Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277–83.PubMedCrossRefGoogle Scholar
  51. 51.
    Ekelund U, Anderssen S, Andersen LB, Riddoch CJ, Sardinha LB, Luan J, et al. Prevalence and correlates of the metabolic syndrome in a population-based sample of European youth. Am J Clin Nutr. 2009;89:90–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Kelishadi R, Razaghi EM, Gouya MM, Ardalan G, Gheiratmand R, Delavari A, et al. Association of physical activity and the metabolic syndrome in children and adolescents: CASPIAN study. Horm Res. 2007;67:46–52.PubMedCrossRefGoogle Scholar
  53. 53.
    Pan Y, Pratt CA. Metabolic syndrome and its association with diet and physical activity in US adolescents. J Am Diet Assoc. 2008;108:276–86. discussion 286.PubMedCrossRefGoogle Scholar
  54. 54.
    Cook S, Auinger P, Li C, Ford ES. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999–2002. J Pediatr. 2008;152:165–70.PubMedCrossRefGoogle Scholar
  55. 55.
    Jago R, Baranowski T, Buse J, Edelstein S, Galassetti P, Harrell J, et al. Prevalence of the metabolic syndrome among a racially/ethnically diverse group of U.S. eighth-grade adolescents and associations with fasting insulin and homeostasis model assessment of insulin resistance levels: Studies to Treat or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Prevention Study Group. Diabetes Care. 2008;31(10):2020–5.CrossRefGoogle Scholar
  56. 56.
    Monzavi R, Dreimane D, Geffner ME, Braun S, Conrad B, Klier M, et al. Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. Pediatrics. 2006;117:e1111–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Steele RM, Brage S, Corder K, Wareham NJ, Ekelund U. Physical activity, cardiorespiratory fitness, and the metabolic syndrome in youth. J Appl Physiol. 2008;105:342–51.PubMedCrossRefGoogle Scholar
  58. 58.
    DuBose KD, Eisenmann JC, Donnelly JE. Aerobic fitness attenuates the metabolic syndrome score in normal-weight, at-risk-for-overweight, and overweight children. Pediatrics. 2007;120:e1262–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Mark AE, Janssen I. Relationship between screen time and metabolic syndrome in adolescents. J Public Health (Oxf). 2008;30:153–60.CrossRefGoogle Scholar
  60. 60.
    Casazza K, Dulin-Keita A, Gower BA, Fernandez JR. Differential influence of diet and physical activity on components of metabolic syndrome in a multiethnic sample of children. J Am Diet Assoc. 2009;109:236–44.PubMedCrossRefGoogle Scholar
  61. 61.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21:1–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Stone NJ, Saxon D. Approach to treatment of the patient with metabolic syndrome:lifestyle therapy. Am J Cardiol. 2005;96:15E–21.PubMedCrossRefGoogle Scholar
  63. 63.
    Chen AK, Roberts CK, Barnard RJ. Effect of a short-term diet and exercise intervention on metabolic syndrome in overweight children. Metab Clin Exp. 2006;55:871–8.PubMedGoogle Scholar
  64. 64.
    Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol. 2002;156:832–41.PubMedCrossRefGoogle Scholar
  65. 65.
    Sacheck J. Pediatric obesity: an inflammatory condition? JPEN J Parenter Enteral Nutr. 2008;32:633–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Kadoglou NPE, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis CD, et al. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil. 2007;14:837–43.PubMedCrossRefGoogle Scholar
  67. 67.
    Goldhammer E, Tanchilevitch A, Maor I, Beniamini Y, Rosenschein U, Sagiv M. Exercise training modulates cytokines activity in coronary heart disease patients. Int J Cardiol. 2005;100:93–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Carrel AL, Clark RR, Peterson SE, Nemeth BA, Sullivan J, Allen DB. Improvement of fitness, body composition, and insulin sensitivity in overweight children in a school-based exercise program: a randomized, controlled study. Arch Pediatr Adolesc Med. 2005;159:963–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Savoye M, Shaw M, Dziura J, Tamborlane WV, Rose P, Guandalini C, et al. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA. 2007;297:2697–704.PubMedCrossRefGoogle Scholar
  70. 70.
    Kim ES, Im J, Kim KC, Park JH, Suh S, Kang ES, et al. Improved insulin sensitivity and adiponectin level after exercise training in obese Korean youth. Obesity (Silver Spring). 2007;15:3023–30.CrossRefGoogle Scholar
  71. 71.
    Reinehr T, Stoffel-Wagner B, Roth CL. Retinol-binding protein 4 and its relation to insulin resistance in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93:2287–93.PubMedCrossRefGoogle Scholar
  72. 72.
    Pinhas-Hamiel O, Lerner-Geva L, Copperman N, Jacobson MS. Insulin resistance and parental obesity as predictors to response to therapeutic life style change in obese children and adolescents 10–18 years old. J Adolesc Health. 2008;43:437–43.PubMedCrossRefGoogle Scholar
  73. 73.
    Rohrer TR, Rizzo VF, Cäsar JJ, Muelbredt O, Sprengart S, Gortner L, et al. Changes in hepatic risk factors, metabolic variables, body composition, and physical fitness in obese children after a one-year weight loss program. J Pediatr Endocrinol Metab. 2008;21:837–45.PubMedGoogle Scholar
  74. 74.
    Nassis GP, Papantakou K, Skenderi K, Triandafillopoulou M, Kavouras SA, Yannakoulia M, et al. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. Metab Clin Exp. 2005;54:1472–9.PubMedGoogle Scholar
  75. 75.
    Faintuch J, Horie LM, Barbeiro HV, Barbeiro DF, Soriano FG, Ishida RK, et al. Systemic inflammation in morbidly obese subjects:response to oral supplementation with alpha-linolenic acid. Obes Surg. 2007;17:341–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Bloedon LT, Balikai S, Chittams J, Cunnane SC, Berlin JA, Rader DJ, et al. Flaxseed and cardiovascular risk factors:results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr. 2008;27:65–74.PubMedGoogle Scholar
  77. 77.
    Molnár D, Decsi T, Koletzko B. Reduced antioxidant status in obese children with multimetabolic syndrome. Int J Obes Relat Metab Disord. 2004;28:1197–202.PubMedCrossRefGoogle Scholar
  78. 78.
    Lütjens A, Smit JL. Effect of biguanide treatment in obese children. Helv Paediatr Acta. 1977;31:473–80.PubMedGoogle Scholar
  79. 79.
    Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 2008;152:817–22.PubMedCrossRefGoogle Scholar
  80. 80.
    Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents:improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91:2074–80.PubMedCrossRefGoogle Scholar
  81. 81.
    Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008;9:567–76.PubMedCrossRefGoogle Scholar
  82. 82.
    Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia:a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008;21:339–48.PubMedGoogle Scholar
  83. 83.
    Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:E55.PubMedCrossRefGoogle Scholar
  84. 84.
    Kay JP, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metab Clin Exp. 2001;50:1457–61.PubMedGoogle Scholar
  85. 85.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMedCrossRefGoogle Scholar
  86. 86.
    Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, Tamborlane W, et al. Treatment options for type 2 diabetes in adolescents and youth:a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8:74–87.PubMedCrossRefGoogle Scholar
  87. 87.
    Gungor N, Hannon T, Libman I, Bacha F, Arslanian S. Type 2 diabetes mellitus in youth:the complete picture to date. Pediatr Clin North Am. 2005;52:1579–609.PubMedCrossRefGoogle Scholar
  88. 88.
    Shalitin S, Abrahami M, Lilos P, Phillip M. Insulin resistance and impaired glucose tolerance in obese children and adolescents referred to a tertiary-care center in Israel. Int J Obes (Lond). 2005;29:571–8.CrossRefGoogle Scholar
  89. 89.
    Fagot-Campagna A, Saaddine JB, Flegal KM, Beckles GL. Diabetes, impaired fasting glucose, and elevated HbA1c in U.S. adolescents:the Third National Health and Nutrition Examination Survey. Diabetes Care. 2001;24:834–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Wabitsch M, Hauner H, Hertrampf M, Muche R, Hay B, Mayer H, et al. Type II diabetes mellitus and impaired glucose regulation in Caucasian children and adolescents with obesity living in Germany. Int J Obes Relat Metab Disord. 2004;28:307–13.PubMedGoogle Scholar
  91. 91.
    Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346:802–10.PubMedCrossRefGoogle Scholar
  92. 92.
    Szamosi A, Czinner A, Szamosi T, Sallai A, Hatunic M, Berla Z, et al. Effect of diet and physical exercise treatment on insulin resistance syndrome of schoolchildren. J Am Coll Nutr. 2008;27:177–83.PubMedGoogle Scholar
  93. 93.
    Libman IM, Barinas-Mitchell E, Bartucci A, Robertson R, Arslanian S. Reproducibility of the oral glucose tolerance test in overweight children. J Clin Endocrinol Metab. 2008;93:4231–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Goran MI, Davis J, Kelly L, Shaibi G, Spruijt-Metz D, Soni SM, et al. Low prevalence of pediatric type 2 diabetes:where’s the epidemic? J Pediatr. 2008;152:753–5.PubMedCrossRefGoogle Scholar
  95. 95.
    Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999;22:345–54.PubMedCrossRefGoogle Scholar
  96. 96.
    Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, et al. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327–34.CrossRefGoogle Scholar
  97. 97.
    Benavides S, Striet J, Germak J, Nahata MC. Efficacy and safety of hypoglycemic drugs in children with type 2 diabetes mellitus. Pharmacotherapy. 2005;25:803–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Shield JPH, Lynn R, Wan KC, Haines L, Barrett TG. Management and 1 year outcome for UK children with type 2 diabetes. Arch Dis Child. 2009;94:206–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes:a randomized, single-blind comparative study. Diabetes Care. 2007;30:790–4.PubMedCrossRefGoogle Scholar
  100. 100.
    Hannon TS, Rao G, Arslanian SA. Childhood obesity and type 2 diabetes mellitus. Pediatrics. 2005;116:473–80.PubMedCrossRefGoogle Scholar
  101. 101.
    Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ. ISPAD Clinical Practice Consensus Guideline 2006–2007. Type 2 diabetes mellitus in the child and adolescent. Pediatr Diabetes. 2008;9:512–26.PubMedCrossRefGoogle Scholar
  102. 102.
    Jacobson-Dickman E, Levitsky L. Oral agents in managing diabetes mellitus in children and adolescents. Pediatr Clin North Am. 2005;52:1689–703.PubMedCrossRefGoogle Scholar
  103. 103.
    Jones KL, Arslanian S, Peterokova VA, Park J, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002;25:89–94.PubMedCrossRefGoogle Scholar
  104. 104.
    Yeap BB. Controversies in type 2 diabetes—An update. Aust Fam Physician. 2009;38:22–5.PubMedGoogle Scholar
  105. 105.
    Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93:3703–16.PubMedCrossRefGoogle Scholar
  106. 106.
    Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31:289–94.PubMedCrossRefGoogle Scholar
  107. 107.
    Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673–7.PubMedCrossRefGoogle Scholar
  108. 108.
    Park E, Wong V, Guan X, Oprescu AI, Giacca A. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. J Endocrinol. 2007;195:323–31.PubMedCrossRefGoogle Scholar
  109. 109.
    Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109:1321–6.PubMedGoogle Scholar
  110. 110.
    Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients:results of a randomised double-blind placebo-controlled study. Diabetologia. 2009;52:385–93.PubMedCrossRefGoogle Scholar
  111. 111.
    McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents:a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115:1948–67.PubMedCrossRefGoogle Scholar
  112. 112.
    Berenson GS, Srnivasan SR. Cardiovascular risk factors in youth with implications for aging:the Bogalusa Heart Study. Neurobiol Aging. 2005;26:303–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks:the Bogalusa Heart Study. Pediatrics. 2006;118:201–6.PubMedCrossRefGoogle Scholar
  114. 114.
    Magnussen CG, Raitakari OT, Thomson R, Juonala M, Patel DA, Viikari JSA, et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood:evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study. Circulation. 2008;117:32–42.PubMedCrossRefGoogle Scholar
  115. 115.
    Steinberger J, Moran A, Hong CP, Jacobs DR, Sinaiko AR. Adiposity in childhood predicts obesity and insulin resistance in young adulthood. J Pediatr. 2001;138:469–73.PubMedCrossRefGoogle Scholar
  116. 116.
    Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198–208.PubMedCrossRefGoogle Scholar
  117. 117.
    Korsten-Reck U, Kromeyer-Hauschild K, Korsten K, Baumstark MW, Dickhuth H, Berg A. Frequency of secondary dyslipidemia in obese children. Vasc Health Risk Manag. 2008;4:1089–94.PubMedGoogle Scholar
  118. 118.
    Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents:the Bogalusa Heart Study. Pediatrics. 1999;103:1175–82.PubMedCrossRefGoogle Scholar
  119. 119.
    Manlhiot C, Larsson P, Gurofsky RC, Smith RW, Fillingham C, Clarizia NA, et al. Spectrum and management of hypertriglyceridemia among children in clinical practice. Pediatrics. 2009;123:458–65.PubMedCrossRefGoogle Scholar
  120. 120.
    Steinberger J, Moorehead C, Katch V, Rocchini AP. Relationship between insulin resistance and abnormal lipid profile in obese adolescents. J Pediatr. 1995;126:690–5.PubMedCrossRefGoogle Scholar
  121. 121.
    Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331–7.PubMedCrossRefGoogle Scholar
  122. 122.
    Kwiterovich PO, Hartmuller G, Van Horn L, Christoffel KK, Gernhoffer N, Gidding S, et al. The Writing Group for the DISC Collaborative Research Group. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC): JAMA. 1995;273(18):1429–35.Google Scholar
  123. 123.
    Jonkers IJAM, Smelt AHM, Princen HMG, Kuipers F, Romijn JA, Boverhof R, et al. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J Nutr. 2006;136:987–91.PubMedGoogle Scholar
  124. 124.
    Engler MM, Engler MB, Malloy MJ, Paul SM, Kulkarni KR, Mietus-Snyder ML. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol. 2005;95:869–71.PubMedCrossRefGoogle Scholar
  125. 125.
    Tolfrey K, Jones AM, Campbell IG. The effect of aerobic exercise training on the lipid-lipoprotein profile of children and adolescents. Sports Med. 2000;29:99–112.PubMedCrossRefGoogle Scholar
  126. 126.
    McCrindle BW, O’Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children:a randomized, crossover trial. J Pediatr. 1997;130:266–73.PubMedCrossRefGoogle Scholar
  127. 127.
    Lauer RM, Clarke WR. Childhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics. 1989;84:633–41.PubMedGoogle Scholar
  128. 128.
    Rademacher E, Jacobs D, Moran A, Steinberger J, Prineas R, Sinaiko A. Relation of blood pressure and body mass index during childhood to cardiovascular risk factor levels in young adults. J Hypertens. 2009;27:1766–74.PubMedCrossRefGoogle Scholar
  129. 129.
    Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113:475–82.PubMedCrossRefGoogle Scholar
  130. 130.
    Paradis G, Lambert M, O’Loughlin J, Lavallée C, Aubin J, Delvin E, et al. Blood pressure and adiposity in children and adolescents. Circulation. 2004;110:1832–8.PubMedCrossRefGoogle Scholar
  131. 131.
    McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr. 2007;150:640–4. 644.e1.PubMedCrossRefGoogle Scholar
  132. 132.
    Sinaiko AR, Donahue RP, Jacobs DR, Prineas RJ. Relation of weight and rate of increase in weight during childhood and adolescence to body size, blood pressure, fasting insulin, and lipids in young adults. The Minneapolis Children’s Blood Pressure Study. Circulation. 1999;99:1471–6.PubMedGoogle Scholar
  133. 133.
    Gidding SS, Bao W, Srinivasan SR, Berenson GS. Effects of secular trends in obesity on coronary risk factors in children:the Bogalusa Heart Study. J Pediatr. 1995;127:868–74.PubMedCrossRefGoogle Scholar
  134. 134.
    Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40:441–7.PubMedCrossRefGoogle Scholar
  135. 135.
    Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007;298:874–9.PubMedCrossRefGoogle Scholar
  136. 136.
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.Google Scholar
  137. 137.
    Rocchini AP, Katch V, Anderson J, Hinderliter J, Becque D, Martin M, et al. Blood pressure in obese adolescents:effect of weight loss. Pediatrics. 1988;82:16–23.PubMedGoogle Scholar
  138. 138.
    Reinehr T, de Sousa G, Toschke AM, Andler W. Long-term follow-up of cardiovascular disease risk factors in children after an obesity intervention. Am J Clin Nutr. 2006;84:490–6.PubMedGoogle Scholar
  139. 139.
    Jiang JX, Xia XL, Greiner T, Lian GL, Rosenqvist U. A two year family based behaviour treatment for obese children. Arch Dis Child. 2005;90:1235–8.PubMedCrossRefGoogle Scholar
  140. 140.
    Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:162–8.PubMedCrossRefGoogle Scholar
  141. 141.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.Google Scholar
  142. 142.
    Franks S. Controversy in clinical endocrinology:diagnosis of polycystic ovarian syndrome:in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91:786–9.PubMedCrossRefGoogle Scholar
  143. 143.
    Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:673–83.PubMedCrossRefGoogle Scholar
  144. 144.
    Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab. 2006;91:1275–83.PubMedCrossRefGoogle Scholar
  145. 145.
    Essah PA, Wickham EP, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50:205–25.PubMedCrossRefGoogle Scholar
  146. 146.
    Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005;90:5711–6.PubMedCrossRefGoogle Scholar
  147. 147.
    Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome:results of a case-control study. J Clin Epidemiol. 1998;51:415–22.PubMedCrossRefGoogle Scholar
  148. 148.
    Littlejohn EE, Weiss RE, Deplewski D, Edidin DV, Rosenfield R. Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2007;20:41–51.PubMedGoogle Scholar
  149. 149.
    de Zegher F, Ibáñez L. Prenatal growth restraint followed by catch-up of weight:a hyperinsulinemic pathway to polycystic ovary syndrome. Fertil Steril. 2006;86(Suppl 1):S4–5.PubMedGoogle Scholar
  150. 150.
    Rosenfield RL. Clinical review:Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:787–96.PubMedCrossRefGoogle Scholar
  151. 151.
    Ibáñez L, Potau N, Carrascosa A. Insulin Resistance, Premature Adrenarche, and a Risk of the Polycystic Ovary Syndrome (PCOS). Trends Endocrinol Metab. 1998;9:72–7.PubMedCrossRefGoogle Scholar
  152. 152.
    Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance:amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 2002;87:1555–9.PubMedCrossRefGoogle Scholar
  153. 153.
    Dunaif A. Insulin resistance and the polycystic ovary syndrome:mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800.PubMedCrossRefGoogle Scholar
  154. 154.
    Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2001;138:38–44.PubMedCrossRefGoogle Scholar
  155. 155.
    Sawathiparnich P, Weerakulwattana L, Santiprabhob J, Likitmaskul S. Obese adolescent girls with polycystic ovary syndrome (PCOS) have more severe insulin resistance measured by HOMA-IR score than obese girls without PCOS. J Med Assoc Thai. 2005;88(Suppl 8):S33–7.PubMedGoogle Scholar
  156. 156.
    Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab. 2003;88:2600–6.PubMedCrossRefGoogle Scholar
  157. 157.
    Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93:4299–306.PubMedCrossRefGoogle Scholar
  158. 158.
    Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome:roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 2001;86:66–71.PubMedCrossRefGoogle Scholar
  159. 159.
    Rossi B, Sukalich S, Droz J, Griffin A, Cook S, Blumkin A, et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:4780–6.PubMedCrossRefGoogle Scholar
  160. 160.
    Martin KA, Chang RJ, Ehrmann DA, Ibáñez L, Lobo RA, Rosenfield RL, et al. Evaluation and treatment of hirsutism in premenopausal women:an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1105–20.PubMedCrossRefGoogle Scholar
  161. 161.
    Legro RS. Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2002;15(Suppl 5):1367–78.PubMedGoogle Scholar
  162. 162.
    Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:3373–80.PubMedCrossRefGoogle Scholar
  163. 163.
    Allen HF, Mazzoni C, Heptulla RA, Murray MA, Miller N, Koenigs L, et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2005;18:761–8.PubMedGoogle Scholar
  164. 164.
    Mastorakos G, Lambrinoudaki I, Creatsas G. Polycystic ovary syndrome in adolescents:current and future treatment options. Paediatr Drugs. 2006;8:311–8.PubMedCrossRefGoogle Scholar
  165. 165.
    Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril. 2006;85:420–7.PubMedCrossRefGoogle Scholar
  166. 166.
    Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril. 2002;77:919–27.PubMedCrossRefGoogle Scholar
  167. 167.
    Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome:systematic review and meta-analysis. BMJ. 2003;327:951–3.PubMedCrossRefGoogle Scholar
  168. 168.
    Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol. 2008;199:596–609.PubMedCrossRefGoogle Scholar
  169. 169.
    Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab. 2000;85:3526–30.PubMedCrossRefGoogle Scholar
  170. 170.
    Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health. 2001;29:160–9.PubMedCrossRefGoogle Scholar
  171. 171.
    Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome:a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009;94:469–76.PubMedCrossRefGoogle Scholar
  172. 172.
    Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:3835–40.PubMedCrossRefGoogle Scholar
  173. 173.
    Narsing Rao L, Jacob JJ, Paul TV, Rajarathinam S, Thomas N, Seshadri MS. Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2009;22:91–5.PubMedCrossRefGoogle Scholar
  174. 174.
    Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy. 2005;25:244–52.PubMedCrossRefGoogle Scholar
  175. 175.
    Angulo P. Nonalcoholic fatty liver disease. Rev Gastroenterol Mex. 2005;70(Suppl 3):52–6.PubMedGoogle Scholar
  176. 176.
    Marion AW, Baker AJ, Dhawan A. Fatty liver disease in children. Arch Dis Child. 2004;89:648–52.PubMedCrossRefGoogle Scholar
  177. 177.
    Manco M, Marcellini M, Devito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond). 2008;32:381–7.CrossRefGoogle Scholar
  178. 178.
    Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, et al. Vitamin E treatment in pediatric obesity-related liver disease:a randomized study. J Pediatr Gastroenterol Nutr. 2004;38:48–55.PubMedCrossRefGoogle Scholar
  179. 179.
    Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1553–61.PubMedCrossRefGoogle Scholar
  180. 180.
    Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, et al. NAFLD in children:a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44:458–65.PubMedCrossRefGoogle Scholar
  181. 181.
    Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1961–1971.e2.PubMedCrossRefGoogle Scholar
  182. 182.
    Manco M, Bottazzo G, DeVito R, Marcellini M, Mingrone G, Nobili V. Nonalcoholic fatty liver disease in children. J Am Coll Nutr. 2008;27:667–76.PubMedGoogle Scholar
  183. 183.
    Burgert TS, Taksali SE, Dziura J, Goodman TR, Yeckel CW, Papademetris X, et al. Alanine aminotransferase levels and fatty liver in childhood obesity:associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab. 2006;91:4287–94.PubMedCrossRefGoogle Scholar
  184. 184.
    Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels:a role for insulin resistance and diabetes. Hepatology. 2008;48:792–8.PubMedCrossRefGoogle Scholar
  185. 185.
    Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr. 2000;136:727–33.PubMedCrossRefGoogle Scholar
  186. 186.
    Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors:NHANES 1999–2004. Gastroenterology. 2007;133:1814–20.PubMedCrossRefGoogle Scholar
  187. 187.
    Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–93.PubMedCrossRefGoogle Scholar
  188. 188.
    Sagi R, Reif S, Neuman G, Webb M, Phillip M, Shalitin S. Nonalcoholic fatty liver disease in overweight children and adolescents. Acta Paediatr. 2007;96:1209–13.PubMedCrossRefGoogle Scholar
  189. 189.
    Jankowska I, Socha P, Pawlowska J, Teisseyre M, Gliwicz D, Czubkowski P, et al. Recurrence of non-alcoholic steatohepatitis after liver transplantation in a 13-yr-old boy. Pediatr Transplant. 2007;11:796–8.PubMedCrossRefGoogle Scholar
  190. 190.
    Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;21:871–9.PubMedCrossRefGoogle Scholar
  191. 191.
    Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article:epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;28:13–24.PubMedCrossRefGoogle Scholar
  192. 192.
    Wang C, Liang L, Fu J, Zou C, Hong F, Xue J, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol. 2008;14:1598–602.PubMedCrossRefGoogle Scholar
  193. 193.
    Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease:2-year follow-up study. Arch Dis Child. 2009;94:437–42.PubMedCrossRefGoogle Scholar
  194. 194.
    Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease:a randomized, controlled trial. Hepatology. 2008;48:119–28.PubMedCrossRefGoogle Scholar
  195. 195.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.PubMedCrossRefGoogle Scholar
  196. 196.
    Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone:a meta-analysis. JAMA. 2007;298:1189–95.PubMedCrossRefGoogle Scholar
  197. 197.
    Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, et al. Metformin use in children with nonalcoholic fatty liver disease:an open-label, 24-month, observational pilot study. Clin Ther. 2008;30:1168–76.PubMedCrossRefGoogle Scholar
  198. 198.
    Lavine JE, Schwimmer JB. Clinical Research Network launches TONIC trial for treatment of nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr. 2006;42:129–30.PubMedCrossRefGoogle Scholar
  199. 199.
    Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr. 2000;136:739–43.PubMedCrossRefGoogle Scholar
  200. 200.
    Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis:results of a randomized trial. Hepatology. 2004;39:770–8.PubMedCrossRefGoogle Scholar
  201. 201.
    Méndez-Sánchez N, González V, Chávez-Tapia N, Ramos MH, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol. 2004;3:108–12.PubMedGoogle Scholar
  202. 202.
    Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:634–8.PubMedGoogle Scholar
  203. 203.
    Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12:224–9.PubMedCrossRefGoogle Scholar
  204. 204.
    de Ferranti S, Mozaffarian D. The perfect storm:obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008;54:945–55.PubMedCrossRefGoogle Scholar
  205. 205.
    Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008;14:741–51.PubMedCrossRefGoogle Scholar
  206. 206.
    Berg AH, Scherer PE. Adipose Tissue, Inflammation, and Cardiovascular Disease. Circ Res. 2005;96:939–49.PubMedCrossRefGoogle Scholar
  207. 207.
    Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol. 2006;57:505–28.PubMedGoogle Scholar
  208. 208.
    de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents:findings from the Third National Health and Nutrition Examination Survey. Circulation. 2004;110:2494–7.PubMedCrossRefGoogle Scholar
  209. 209.
    Alberti G, Zimmet P, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The IDF consensus definition of the metabolic syndrome in children and adolescents. In: International Diabetes Federation. 2007. Accessed 5 Aug 2009.
  210. 210.
    American Diabetes Association. Standards of Medical Care in Diabetes–2009. Diabetes Care. 2009;32:S13–61.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Katie Larson Ode
    • 1
  • Brigitte I. Frohnert
    • 1
  • Brandon M. Nathan
    • 1
  1. 1.Division of Pediatric EndocrinologyUniversity of MinnesotaMinneapolisUSA

Personalised recommendations